Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

China · Delayed Price · Currency is CNY

21.22

+0.29 (1.39%)

At close: Aug 20, 2026

34.47% (1Y)

Market Cap	8.42B +34.5%
Revenue (ttm)	2.21B +24.3%
Net Income	254.51M +773.1%
EPS	0.64 +774.9%
Shares Out	396.81M
PE Ratio	33.10
Forward PE	n/a
Dividend	0.05 (0.24%)
Ex-Dividend Date	Jun 26, 2026

Volume	9,195,922
Open	21.14
Previous Close	20.93
Day's Range	21.03 - 21.73
52-Week Range	13.97 - 35.58
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 2,258

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301246

Full Company Profile

Financial Performance

In 2025, SHE:301246's revenue was 1.94 billion, an increase of 9.53% compared to the previous year's 1.77 billion. Earnings were 119.05 million, an increase of 131.33%.

Financial Statements